CLINICAL_TRIALS
trial_result
· 2022-07-01
Clinical Trial Update: Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers [Phase 2]
Summary
Phase 2 clinical trial update evaluating carfilzomib for advanced neuroendocrine cancers has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: SCRI Development Innovations, LLC | Conditions: Neuroendocrine Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-07-01